SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

With no major difference for the quarter endedMarch 2026 , the total revenue stood at Rs. 9891.50  millions.Net profit stood at Rs. 2749.40  millions  compared to Rs. 2601.40 millions in the corresponding previous quarter,high by 5.69%.Operating profit for the quarter ended March 2026 rose to 3829.00 millions as compared to 3702.00 millions of corresponding quarter ended March 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 9891.50 9660.80 2.39 37902.00 37234.90 1.79 37902.00 37234.90 1.79
Other Income 357.10 394.60 -9.50 1425.60 1425.60 0.00 1425.60 1425.60 0.00
PBIDT 3829.00 3702.00 3.43 14427.60 13118.50 9.98 14427.60 13118.50 9.98
Interest 6.10 5.80 5.17 27.30 13.10 108.40 27.30 13.10 108.40
PBDT 3822.90 3696.20 3.43 14426.70 13152.30 9.69 14426.70 13152.30 9.69
Depreciation 131.70 147.20 -10.53 664.40 667.90 -0.52 664.40 667.90 -0.52
PBT 3691.20 3549.00 4.01 13762.30 12484.40 10.24 13762.30 12484.40 10.24
TAX 941.80 947.60 -0.61 3644.10 3293.80 10.64 3644.10 3293.80 10.64
Deferred Tax 69.40 54.20 28.04 94.60 62.00 52.58 94.60 62.00 52.58
PAT 2749.40 2601.40 5.69 10118.20 9190.60 10.09 10118.20 9190.60 10.09
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 38.71 38.32 1.02 38.07 35.23 8.04 38.07 35.23 8.04

Glaxosmithkline Phar Share Price

2435.50 -7.60 (-0.31%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: